TCTMD

Elixir Medical Announces Schedule of Programs for TCT 2014

First Live Case Transmission in the US of the CE Mark-approved Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System Sunnyvale, CA—Elixir Medical Corporation, a developer of ...
Yahoo

TCT 2025: Elixir Medical’s arterial implant drops coronary events by nearly 50%

Elixir Medical's DynamX bioadaptor has been shown to diminish target lesion failure (TLF) by 48% in a landmark clinical trial. Image credit: Jo Panuwat D via Shutterstock.com. Elixir Medical’s ...
Medical Device and Diagnostic Industry (MD+DI)

How An FDA Breakthrough Device Could Transform Coronary Care

Elixir Medical's DynamX Bioadaptor restores natural artery function, reducing the risk of future cardiac events.
TCTMD

Elixir Medical Corporation Announces Outstanding Three-year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System(2)

Results Set a High Standard in Sustained Long Term Clinical Outcomes Sunnyvale, CA— Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced ...
Business Wire

Elixir Medical Expands Leadership Team With Addition of Alexey Nepogodiev as Executive Vice President, Global Marketing

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alexey (Alex) Nepogodiev as Executive Vice President ...
Business Wire

Elixir Medical Strengthens Its Commercial Capabilities With the Addition of Alaeddin Ahram as Executive Vice President, International

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alaeddin Ahram as Executive Vice President, ...
Business Insider

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard ...

Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor is the first interventional technology to ...
Seeking Alpha

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years

Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX ® compared to DES— —Significantly lower ...
Yahoo Finance

Elixir Medical Highlights Results From “Real World” MY-IVL Study Demonstrating Performance of LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in ...

MILPITAS, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, announced results from the MY-IVL Study at the Transcatheter ...
FiercePharma

Elixir Medical Announces Excellent Six-Month Safety and Efficacy Results for the CE-Marked Fully Bioresorbable DESolve® Novolimus Eluting Coronary Scaffold System at Late ...

Elixir Medical Announces Excellent Six-Month Safety and Efficacy Results for the CE-Marked Fully Bioresorbable DESolve® Novolimus Eluting Coronary Scaffold System at Late Breaking Clinical Trial ...
BioWorld

Items Tagged with 'Elixir Medical Corp.'

Receipt of EU MDR CE mark may not be a magic potion, but Elixir Medical Corp. is certainly feeling a boost from the regulatory nod for its mechanical Lithix hertz contact intravascular lithotripsy ...